Navigation Links
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
Date:10/17/2009

linical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderate to severely active rheumatoid arthritis. Cimzia® was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn's disease who have not responded adequately to conventional treatment in September 2007. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A.

IMPORTANT SAFETY INFORMATION

Risk of Serious Infections

Patients treated with Cimzia® are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Cimzia® should be discontinued if a patient develops a serious infection or sepsis. Reported infections include:

  • Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Cimzia® use and during therapy. Treatment for latent infection should be initiated prior to Cimzia® use.
  • Invasive fungal infections, including histoplasmosis , coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric
    '/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
2. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
3. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
4. Tiny test tube experiment shows reaction of melting materials at the nano scale
5. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
6. Topical erectile dysfunction therapy shows promise
7. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
8. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
9. Video shows nanotube spins as it grows
10. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
11. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015  Resolution Bioscience announced today the ... ALK TM , a blood-based liquid biopsy for an ... carcinoma (NSCLC), the most common form of this cancer. ... guide patients to personalized therapies and direct them into ... The Department of Health, the CLIA authority in ...
(Date:5/20/2015)... TRIANGLE PARK, North Carolina , ... weltweit führende Unternehmen für klinische Logistik ... Finanzergebnisse für das Geschäftsjahr 2014, das ... und eingereicht. Das Unternehmen hat die ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ., (GGI) ... announce they are donating 10,010 vaccines today in recognition ... effort and commitment of clinical trial volunteers who participated ... 2014. , With a mission to advance global ... participation, GGI supports International Clinical Trials Day and how ...
(Date:5/20/2015)... , May 20, 2015  OncoSec Medical ... intratumoral cancer immunotherapies, will present data from ongoing ... Academy of Sciences, Emerging Approaches to Cancer Immunotherapy. ... , MD, and Chief Medical Officer Mai. H. ... Expression of Plasmid IL-12 Can Increase CD8 TILs ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 3OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 4
... Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back... -- BEIJING, Aug. 24 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... and BEDMINSTER, N.J., Aug. 23 Archimedes ... pain, neurology and critical care sectors, announced today the ... Jersey. Archimedes has offices in a number ... in Europe.  The opening of its US office marks ...
... Bjerke Appointed as new CEO for Karolinska Development -- STOCKHOLM, August 23, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives 2Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives 3Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives 4Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives 5Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives 6Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey 2Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey 3Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey 4Torbjorn Bjerke Appointed as new CEO for Karolinska Development 2Torbjorn Bjerke Appointed as new CEO for Karolinska Development 3Torbjorn Bjerke Appointed as new CEO for Karolinska Development 4Torbjorn Bjerke Appointed as new CEO for Karolinska Development 5Torbjorn Bjerke Appointed as new CEO for Karolinska Development 6
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... Questions about the existence of life in outer space may ... Houston professor. , Understanding how life evolved on Earth is ... universe one might find life and what it might be ... and biochemistry. Fox is finishing work on a three-year research ...
... of one family of antibiotics kill bacteria that make ... developers make slight changes to these antibiotics to make ... Irina Artsimovitch, a study co-author and an assistant professor ... studied belong to the rifamycin family. Until now, researchers ...
... to seven million years ago, when the lineage of ... rutabagas and turnips may have been one of the ... the University of Minnesota and Richard Wrangham of Harvard ... roots and tubers must have sustained our ancestors who ...
Cached Biology News:Evolution of life on Earth may hold key to finding life in outer space 2Evolution of life on Earth may hold key to finding life in outer space 3Researchers find how some antibiotics kill bacteria 2Researchers find how some antibiotics kill bacteria 3“Hitchhiking?Viruses as Cancer Drug Delivery System 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
Biology Products: